TC
MDGL icon

TFS Capital’s Madrigal Pharmaceuticals MDGL Stock Holding History

TFS Capital’s Portfolio MDGL Stock Details MDGL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-12,703
Closed -$207K – 217
2017
Q2 		$207K Buy
+12,703
New +$199K 0.08% 436
2016
Q1 		– Sell
-914
Closed -$11K – 1055
2015
Q4 		$11K Sell
914
-9,582
-91% -$263K ﹤0.01% 731
2015
Q3 		$639K Buy
10,496
+9,105
+655% +$657K 0.06% 450
2015
Q2 		$109K Sell
1,391
-617
-31% -$51.8K 0.01% 807
2015
Q1 		$136K Buy
+2,008
New +$172K 0.01% 842

Other funds holding MDGL

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
FCMI
Foresite Capital Management III Larkspur, California $37.9M AUM 6.87% 1-Year Est. Return
AC
Ascend Capital Orinda, California $1.99B AUM 10.36% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

TFS Capital's MDGL Position: Q3 2017 in Review

TFS Capital sold out of Madrigal Pharmaceuticals (MDGL) in Q3 2017, closing a stake of 12,703 shares — an estimated $207K sold.

TFS Capital first reported a position in MDGL in Q1 2015 and held it in 5 quarters. The position peaked at $639K in Q3 2015. 53 funds tracked by Wall St. Rank hold MDGL as of Q3 2017.

  • TFS Capital reported no remaining Madrigal Pharmaceuticals position as of Q3 2017 after selling out during the quarter.
  • TFS Capital sold 12,703 Madrigal Pharmaceuticals shares in Q3 2017, an estimated $207K.
  • TFS Capital first reported a position in Madrigal Pharmaceuticals in Q1 2015 and held it in 5 quarters.
  • TFS Capital's Madrigal Pharmaceuticals position peaked at $639K in Q3 2015.
  • 53 funds tracked by Wall St. Rank held Madrigal Pharmaceuticals as of Q3 2017.

Based on TFS Capital's 13F filing for Q3 2017.